PMID- 30617277
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20220416
IS  - 2092-6413 (Electronic)
IS  - 1226-3613 (Print)
IS  - 1226-3613 (Linking)
VI  - 51
IP  - 1
DP  - 2019 Jan 7
TI  - Development of immunocompatible pluripotent stem cells via CRISPR-based human 
      leukocyte antigen engineering.
PG  - 1-11
LID - 10.1038/s12276-018-0190-2 [doi]
LID - 3
AB  - Pluripotent stem cell transplantation is a promising regenerative strategy for 
      treating intractable diseases. However, securing human leukocyte antigen 
      (HLA)-matched donor stem cells is extremely difficult. The traditional approach 
      for generating such cells is to establish homozygous pluripotent stem cell lines. 
      Unfortunately, because of HLA diversity, this strategy is too time-consuming to 
      be of practical use. HLA engineering of donor stem cells has been proposed 
      recently as a means to evade graft-versus-host rejection in stem cell 
      allotransplantation. This approach would be advantageous in both time and cost to 
      the traditional method, but its feasibility must be investigated. In this study, 
      we used CRISPR/Cas9 to knockout HLA-B from inducible pluripotent stem cells 
      (iPSCs) with heterogenous HLA-B and showed that the HLA-B knockout iPSCs resulted 
      in less immunogenicity in HLA-B antisera than that in the control. Our results 
      support the feasibility of HLA-engineered iPSCs in stem cell allotransplantation.
FAU - Jang, Yeonsue
AU  - Jang Y
AD  - Catholic iPSC Research Center, College of Medicine, The Catholic University of 
      Korea, Seoul, 137-701, South Korea.
AD  - Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's 
      Hospital, Seoul, 137-701, South Korea.
FAU - Choi, Jinhyeok
AU  - Choi J
AD  - Catholic iPSC Research Center, College of Medicine, The Catholic University of 
      Korea, Seoul, 137-701, South Korea.
FAU - Park, Narae
AU  - Park N
AD  - Catholic iPSC Research Center, College of Medicine, The Catholic University of 
      Korea, Seoul, 137-701, South Korea.
FAU - Kang, Jaewoo
AU  - Kang J
AD  - Catholic iPSC Research Center, College of Medicine, The Catholic University of 
      Korea, Seoul, 137-701, South Korea.
FAU - Kim, Myungshin
AU  - Kim M
AUID- ORCID: 0000-0001-8632-0168
AD  - Department of Laboratory Medicine, College of Medicine, The Catholic University 
      of Korea, Seoul, 137-701, South Korea.
AD  - Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, 137-701, South Korea.
FAU - Kim, Yonggoo
AU  - Kim Y
AD  - Department of Laboratory Medicine, College of Medicine, The Catholic University 
      of Korea, Seoul, 137-701, South Korea.
AD  - Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, Seoul, 137-701, South Korea.
FAU - Ju, Ji Hyeon
AU  - Ju JH
AD  - Catholic iPSC Research Center, College of Medicine, The Catholic University of 
      Korea, Seoul, 137-701, South Korea. juji@catholic.ac.kr.
AD  - Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's 
      Hospital, Seoul, 137-701, South Korea. juji@catholic.ac.kr.
AD  - Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's 
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, 137-701, 
      South Korea. juji@catholic.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190107
PL  - United States
TA  - Exp Mol Med
JT  - Experimental & molecular medicine
JID - 9607880
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Animals
MH  - *CRISPR-Cas Systems
MH  - Cells, Cultured
MH  - HLA Antigens/*genetics
MH  - *Histocompatibility
MH  - Humans
MH  - Induced Pluripotent Stem Cells/cytology/*immunology/transplantation
MH  - Male
MH  - Mice
MH  - Mice, Nude
PMC - PMC6323054
COIS- The authors declare that they have no conflict of interest.
EDAT- 2019/01/09 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/01/07
CRDT- 2019/01/09 06:00
PHST- 2018/03/18 00:00 [received]
PHST- 2018/09/09 00:00 [accepted]
PHST- 2018/08/06 00:00 [revised]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/01/07 00:00 [pmc-release]
AID - 10.1038/s12276-018-0190-2 [pii]
AID - 190 [pii]
AID - 10.1038/s12276-018-0190-2 [doi]
PST - epublish
SO  - Exp Mol Med. 2019 Jan 7;51(1):1-11. doi: 10.1038/s12276-018-0190-2.